Nicolas Dumaz

ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Topics

Tyrosine Kinase

Metastatic Colorectal Cancer

Ulcerative Colitis

Top Venues

Molecular cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Coralie Reger De Moura, Baptiste Louveau, Fanélie Jouenne, Paul Vilquin, Maxime Battistella, Yaelle Bellahsen-Harrar, Aurélie Sadoux, Suzanne Menashi, Nicolas Dumaz, Céleste Lebbé, Samia Mourah
Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1. Oncogene 43 (21) (2024)
Coralie Reger De Moura, Baptiste Louveau, Fanélie Jouenne, Paul Vilquin, Maxime Battistella, Yaelle Bellahsen-Harrar, Aurélie Sadoux, Suzanne Menashi, Nicolas Dumaz, Céleste Lebbé, Samia Mourah
Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1. Oncogene 43 (21) (2024)
Coralie Reger De Moura, Baptiste Louveau, Fanélie Jouenne, Paul Vilquin, Maxime Battistella, Yaelle Bellahsen-Harrar, Aurélie Sadoux, Suzanne Menashi, Nicolas Dumaz, Céleste Lebbé, Samia Mourah
Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1. Oncogene (2024)
Julie Delyon, Anaïs Vallet, Mélanie Bernard-Cacciarella, Isabelle Kuzniak, Coralie Reger De Moura, Baptiste Louveau, Fanélie Jouenne, Samia Mourah, Céleste Lebbé, Nicolas Dumaz
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro. Cancers 15 (11) (2023)
Alexandra Landras, Coralie Reger De Moura, Bruno O Villoutreix, Maxime Battistella, Aurélie Sadoux, Nicolas Dumaz, Suzanne Menashi, Juan Fernández-Recio, Céleste Lebbé, Samia Mourah
Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction. Oncogene 41 (15) (2022)
Ahlem Jebali, Maxime Battistella, Céleste Lebbé, Nicolas Dumaz
RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy. Biomedicines 9 (10) (2021)
Pauline Tétu, Julie Delyon, Jocelyne André, Coralie Reger de Moura, Malak Sabbah, Ghanem E Ghanem, Maxime Battistella, Samia Mourah, Céleste Lebbé, Nicolas Dumaz
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma. Cancers 12 (5) (2020)
Nicolas Dumaz, Fanélie Jouenne, Julie Delyon, Samia Mourah, Armand Bensussan, Céleste Lebbé
Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Cancers 11 (8) (2019)
Baptiste Louveau, Fanelie Jouenne, Coralie Reger de Moura, Aurelie Sadoux, Barouyr Baroudjian, Julie Delyon, Florian Herms, Adele De Masson, Laetitia Da Meda, Maxime Battistella, Nicolas Dumaz, Celeste Lebbe, Samia Mourah
Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. Cancers 11 (8) (2019)
Ahlem Jebali, Nicolas Dumaz
The role of RICTOR downstream of receptor tyrosine kinase in cancers. Molecular cancer 17 (1) (2018)